FCA
CKPT

Fortis Capital Advisors’s Checkpoint Therapeutics CKPT Stock Holding History

Fortis Capital Advisors’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-52
Closed -$117 – 197
2023
Q1 		$117 Hold
52
– – ﹤0.01% 652
2022
Q4 		$266 Buy
+52
New +$375 ﹤0.01% 647

Other funds holding CKPT

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

Fortis Capital Advisors's CKPT Position: Q2 2023 in Review

Fortis Capital Advisors sold out of Checkpoint Therapeutics (CKPT) in Q2 2023, closing a stake of 52 shares — an estimated $117 sold.

Fortis Capital Advisors first reported a position in CKPT in Q4 2022 and held it in 2 quarters. The position peaked at $266 in Q4 2022. 34 funds tracked by Wall St. Rank hold CKPT as of Q2 2023.

  • Fortis Capital Advisors reported no remaining Checkpoint Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Fortis Capital Advisors sold 52 Checkpoint Therapeutics shares in Q2 2023, an estimated $117.
  • Fortis Capital Advisors first reported a position in Checkpoint Therapeutics in Q4 2022 and held it in 2 quarters.
  • Fortis Capital Advisors's Checkpoint Therapeutics position peaked at $266 in Q4 2022.
  • 34 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2023.

Based on Fortis Capital Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.